Gilteritinib Clinical Trials
18 recruitingDrug
Phase 111Phase 210Not Applicable1Phase 31
Showing 1–18 of 18 trials
Recruiting
Phase 2
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia
National Cancer Institute (NCI)147 enrolled221 locationsNCT06317649
Recruiting
Phase 2
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Acute Myeloid LeukemiaMyelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic Therapy+2 more
National Cancer Institute (NCI)2,000 enrolled345 locationsNCT05564390
Recruiting
Phase 1
A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia (AML)
Memorial Sloan Kettering Cancer Center18 enrolled7 locationsNCT05756777
Recruiting
Phase 1Phase 2
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Multiple MyelomaMyelodysplastic SyndromesLeukemia, Myeloid, Acute+1 more
Sumitomo Pharma America, Inc.606 enrolled104 locationsNCT04988555
Recruiting
Phase 3
MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib
Acute Myeloid Leukemia (AML)Maintenance TherapyAllogeneic Hematopoietic Cell Transplantation (HCT)+3 more
The First Affiliated Hospital of Soochow University594 enrolled2 locationsNCT07463651
Recruiting
Phase 1
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaAcute Myeloid Leukemia With FLT3/ITD Mutation+2 more
Uma Borate30 enrolled3 locationsNCT06222580
Recruiting
Phase 1Phase 2
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Acute Myeloid LeukemiaMyelodysplastic SyndromeRecurrent Acute Myeloid Leukemia+1 more
M.D. Anderson Cancer Center42 enrolled1 locationNCT05010122
Recruiting
Phase 1
Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission
Acute Myeloid Leukemia
M.D. Anderson Cancer Center125 enrolled1 locationNCT05010772
Recruiting
Phase 2
Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
Targeted TherapyIDH1-Mutated MalignanciesMutations
M.D. Anderson Cancer Center68 enrolled1 locationNCT07032727
Recruiting
Phase 1
Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML
Acute Myeloid Leukemia With FLT3/ITD Mutation
H. Lee Moffitt Cancer Center and Research Institute22 enrolled1 locationNCT05024552
Recruiting
Phase 1
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Acute Myeloid LeukemiaAcute LeukemiaAML+9 more
Kura Oncology, Inc.171 enrolled44 locationsNCT06001788
Recruiting
Phase 1Phase 2
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Recurrent Chronic Myelomonocytic LeukemiaRefractory Chronic Myelomonocytic LeukemiaRecurrent Acute Myeloid Leukemia+3 more
M.D. Anderson Cancer Center97 enrolled1 locationNCT04140487
Recruiting
Phase 1Phase 2
A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
Myeloid Leukemia
M.D. Anderson Cancer Center20 enrolled1 locationNCT06235801
Recruiting
Phase 2
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Acute Myeloid LeukemiaMyelodysplastic SyndromeBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive+11 more
M.D. Anderson Cancer Center508 enrolled1 locationNCT02115295
Recruiting
Phase 1
Gilteritinib for the Treatment of ALK NSCLC
Stage IV Lung Cancer AJCC v8Lung Non-Small Cell Carcinoma
University of Michigan Rogel Cancer Center30 enrolled3 locationsNCT06225427
Recruiting
Phase 1Phase 2
The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation
AMLFLT3 Gene Mutation
Institute of Hematology & Blood Diseases Hospital, China36 enrolled1 locationNCT06561880
Recruiting
Not Applicable
MRD-positive AML Clinical Study
AML, Adult
Institute of Hematology & Blood Diseases Hospital, China120 enrolled1 locationNCT07131059
Recruiting
Phase 2
Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML
Acute Myeloid LeukemiaAML, Childhood
Children's Hospital of Soochow University500 enrolled13 locationsNCT06221683